WGS Stock Forecast & Price Target

GeneDx Holdings is viewed favorably because its core rare-disease market remains robust, with Q3 delivering +25% Y/Y volume growth and top-line results that matched estimates, while the company’s long-term shift from exomes to higher-value genomes supports ASP expansion and better reimbursement. The thesis is further strengthened by improving coverage dynamics, including Medi-Cal’s $5,000 genome reimbursement and Carelon’s updated outpatient genome policy, which together reduce reimbursement uncertainty and can accelerate adoption of whole-genome sequencing as a first-line diagnostic. Despite near-term noise from RCM and EMR onboarding and a modest ASP headwind next year, leadership changes, strong cash of $133M in Q2, and expanding pediatric and NICU opportunities support profitability and scale.

GeneDx Holdings is facing a more challenging fundamental setup as management lowered its 2026 volume guide to at least 28% from 30%+, and even its Q4'26 revenue guide of $135M came in below expectations, signaling softer near-term execution despite seasonally stronger demand. The company also highlighted a sizable reimbursement overhang from PAMA, with about 45% of revenue potentially exposed to an estimated 15% CLFS price cut, which could create a 6.75% revenue headwind and reduce 2027 revenue by roughly $35M-$40M. Reflecting those pressures, estimates for 2027 and 2028 revenue and adjusted net income were cut, while the business still must fund growth investments in pediatricians, NICU sales, and newborn screening.